Topics

CNS Tumors | Treatment | Side effects | Temozolomide

Home > Publications > Topics > CNS Tumors > Treatment > Side effects > Temozolomide

Lin Y, Deng M, Xu S, Chen C, Ding J.
Post-Marketing Safety of Temozolomide: A Pharmacovigilance Study Based on the Food and Drug Administration Adverse Event Reporting System.
Oncology. 2025 Jan 24:1-9. doi: 10.1159/000542989. PMID: 39864433. Observational study˰ ˍ